HTG Molecular Diagnostics (NASDAQ: HTGM) is one of 24 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its competitors? We will compare HTG Molecular Diagnostics to related businesses based on the strength of its earnings, profitability, risk, valuation, institutional ownership, dividends and analyst recommendations.
Insider & Institutional Ownership
8.4% of HTG Molecular Diagnostics shares are held by institutional investors. Comparatively, 57.8% of shares of all “Analytical instruments” companies are held by institutional investors. 7.6% of HTG Molecular Diagnostics shares are held by company insiders. Comparatively, 13.2% of shares of all “Analytical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
HTG Molecular Diagnostics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, HTG Molecular Diagnostics’ competitors have a beta of 1.11, indicating that their average stock price is 11% more volatile than the S&P 500.
Valuation and Earnings
This table compares HTG Molecular Diagnostics and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|HTG Molecular Diagnostics||$14.76 million||-$18.96 million||-1.98|
|HTG Molecular Diagnostics Competitors||$1.09 billion||$107.48 million||22.73|
HTG Molecular Diagnostics’ competitors have higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and price targets for HTG Molecular Diagnostics and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|HTG Molecular Diagnostics||0||0||3||0||3.00|
|HTG Molecular Diagnostics Competitors||104||743||1112||47||2.55|
HTG Molecular Diagnostics currently has a consensus target price of $6.67, indicating a potential upside of 88.32%. As a group, “Analytical instruments” companies have a potential upside of 11.99%. Given HTG Molecular Diagnostics’ stronger consensus rating and higher probable upside, research analysts clearly believe HTG Molecular Diagnostics is more favorable than its competitors.
This table compares HTG Molecular Diagnostics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|HTG Molecular Diagnostics||-105.56%||N/A||-95.65%|
|HTG Molecular Diagnostics Competitors||-224.43%||-30.94%||-12.79%|
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company's products, HTG Edge and HTG EdgeSeq platforms include instrumentation (or platforms), consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq lymphoma panel; HTG EdgeSeq microRNA whole-transcriptome assay; and HTG EdgeSeq DLBCL cell of origin assay. It also provides sample processing and molecular profiling of retrospective cohorts through its VERI/O laboratory; and designs custom panels for biopharmaceutical customers and research services, resulting from research and development collaboration agreements with biopharmaceutical customers. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company has a research collaboration with Insituto Valenciano de Oncologia on breast cancer recurrence risk. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.